TrialThe New England journal of medicine2020
Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Raymond S Douglas et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
364 papers cite itlatest 60 shown
this paperpooled ittrialcites it